Central India Chronicle

Critical Limb Ischemia Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Medtronic plc, Eli Lilly, Abbott, LimFlow SA, Cardiovascular Systems, Inc,

 Breaking News
  • No posts were found

Critical Limb Ischemia Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Medtronic plc, Eli Lilly, Abbott, LimFlow SA, Cardiovascular Systems, Inc,

August 29
09:30 2023
Critical Limb Ischemia Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Medtronic plc, Eli Lilly, Abbott, LimFlow SA, Cardiovascular Systems, Inc,
“Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Critical Limb Ischemia, historical and forecasted epidemiology as well as the Critical Limb Ischemia market trends in the 7MM.

DelveInsight’s “Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Critical Limb Ischemia, historical and forecasted epidemiology as well as the Critical Limb Ischemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Critical Limb Ischemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Critical Limb Ischemia Market Forecast

 

Some of the key facts of the Critical Limb Ischemia Market Report: 

  • The Critical Limb Ischemia market size was valued approximately USD 1,727 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In June 2022, Critical limb ischemia (CLI) is a clinical phenomenon associated with peripheral arterial disease (PAD) of the lower extremities and ischemic tissue loss, such as non-healing sores or gangrene. The macrovascular lesions cause a decline in distal perfusion in CLI, the final stage of PAD. The disease significantly alters the microcirculation exchange and nutrient blood flow to the tissues.
  • In March 2022, The PROMISE II U.S. pivotal trial of the ground-breaking LimFlow device, which has no other treatment choices for patients with chronic limb-threatening ischemia, is now fully enrolled
  • In 2020, 2,053,158 instances of Critical Limb Ischemia were diagnosed as being widespread throughout seven large markets (7MM)
  • There were 869,822 diagnosed prevalent Critical Limb Ischemia cases in EU-5 in 2020
  • In the US, there were 1,073,553 diagnosed prevalent cases of Critical Limb Ischemia in 2020
  • Rutherford’s classification criteria have been used to stratify Critical Limb Ischemia severity. According to projections, there will be 360,714, 478,805, and 234,035 Class 4, Class 5, and Class 6 cases in the US in 2020
  • Key Critical Limb Ischemia Companies: Medtronic plc, LimFlow SA, Cardiovascular Systems, Inc, Eli Lilly and Company, Abbott Laboratories, Ixaka Ltd (formerly known as Rexgenero), Hemostemix Inc., Caladrius Biosciences, Stempeutics Research Pvt Ltd, United Therapeutics, Sangart, and others
  • Key Critical Limb Ischemia Therapies: REX-001, ACP-01, Honedra, mesenchymal stem cells, treprostinil dienthanolmine, Hemospan (MP4OX), and others
  • The majority of the new Critical Limb Ischemia treatment options are cell treatments. The highlighted emerging therapeutics are Honedra from Caladrius Bioscience, Hemostemix’s ACP-01, and Ixaka’s REX-001.
  • The Critical Limb Ischemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Critical Limb Ischemia pipeline products will significantly revolutionize the Critical Limb Ischemia market dynamics.

 

Critical Limb Ischemia Overview

Critical limb ischemia (CLI) is a clinical phenomenon associated with peripheral arterial disease (PAD) of the lower extremities and ischemic tissue loss, such as non-healing sores or gangrene. The macro vascular lesions cause a decline in distal perfusion in CLI, the final stage of PAD. The disease significantly alters the microcirculation exchange and nutrient blood flow to the tissues.

 

Get a Free sample for the Critical Limb Ischemia Market Report 

https://www.delveinsight.com/report-store/critical-limb-ischemia-market

 

Critical Limb Ischemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Critical Limb Ischemia Epidemiology Segmentation:

The Critical Limb Ischemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Critical Limb Ischemia
  • Prevalent Cases of Critical Limb Ischemia by severity
  • Gender-specific Prevalence of Critical Limb Ischemia
  • Diagnosed Cases of Episodic and Chronic Critical Limb Ischemia

 

Download the report to understand which factors are driving Critical Limb Ischemia epidemiology trends @ Critical Limb Ischemia Epidemiology Forecast

 

Critical Limb Ischemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Critical Limb Ischemia market or expected to get launched during the study period. The analysis covers Critical Limb Ischemia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Critical Limb Ischemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Critical Limb Ischemia Therapies and Key Companies

  • REX-001: Ixaka Ltd (formerly known as Rexgenero
  • ACP-01: Hemostemix Inc.
  • Honedra: Caladrius Biosciences
  • mesenchymal stem cells: Stempeutics Research Pvt Ltd
  • treprostinil dienthanolmine: United Therapeutics
  • Hemospan (MP4OX): Sangart

 

Discover more about therapies set to grab major Critical Limb Ischemia market share @ Critical Limb Ischemia Treatment Market

 

Critical Limb Ischemia Market Drivers

  • Rich emerging Critical Limb Ischemia pipeline
  • Increasing Critical Limb Ischemia prevalence
  • Less competition for upcoming Critical Limb Ischemia therapies
  • Companies shifting their focus to this area, despite low awareness of the disease

 

Critical Limb Ischemia Market Barriers

  • Lack of approved pharmacological therapies
  • Challenging disease in terms of management
  • Low awareness
  • High economic burden
  • Failure of drugs in clinical development

 

Scope of the Critical Limb Ischemia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Critical Limb Ischemia Companies: Medtronic plc, LimFlow SA, Cardiovascular Systems, Inc, Eli Lilly and Company, Abbott Laboratories, Ixaka Ltd (formerly known as Rexgenero), Hemostemix Inc., Caladrius Biosciences, Stempeutics Research Pvt Ltd, United Therapeutics, Sangart, and others
  • Key Critical Limb Ischemia Therapies: REX-001, ACP-01, Honedra, mesenchymal stem cells, treprostinil dienthanolmine, Hemospan (MP4OX), and others
  • Critical Limb Ischemia Therapeutic Assessment: Critical Limb Ischemia current marketed and Critical Limb Ischemia emerging therapies
  • Critical Limb Ischemia Market Dynamics: Critical Limb Ischemia market drivers and Critical Limb Ischemia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Critical Limb Ischemia Unmet Needs, KOL’s views, Analyst’s views, Critical Limb Ischemia Market Access and Reimbursement 

 

To know more about Critical Limb Ischemia companies working in the treatment market, visit @ Critical Limb Ischemia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Critical Limb Ischemia Market Report Introduction

2. Executive Summary for Critical Limb Ischemia

3. SWOT analysis of Critical Limb Ischemia

4. Critical Limb Ischemia Patient Share (%) Overview at a Glance

5. Critical Limb Ischemia Market Overview at a Glance

6. Critical Limb Ischemia Disease Background and Overview

7. Critical Limb Ischemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Critical Limb Ischemia 

9. Critical Limb Ischemia Current Treatment and Medical Practices

10. Critical Limb Ischemia Unmet Needs

11. Critical Limb Ischemia Emerging Therapies

12. Critical Limb Ischemia Market Outlook

13. Country-Wise Critical Limb Ischemia Market Analysis (2019–2032)

14. Critical Limb Ischemia Market Access and Reimbursement of Therapies

15. Critical Limb Ischemia Market Drivers

16. Critical Limb Ischemia Market Barriers

17.  Critical Limb Ischemia Appendix

18. Critical Limb Ischemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services